Patents by Inventor Mark D. Adams

Mark D. Adams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20030078391
    Abstract: The present invention relates to a human CTGF-2 polypeptide and DNA (RNA) encoding such polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonist/inhibitors against such polypeptide. Also provided are methods of using the polypeptide therapeutically for enhancing the repair of connective and support tissue, promoting the attachment, fixation and stabilization of tissue implants and enhancing wound healing. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention are also disclosed.
    Type: Application
    Filed: November 15, 2002
    Publication date: April 24, 2003
    Applicant: Human Genome Sciences, Inc.
    Inventors: Haodong Li, Mark D. Adams
  • Patent number: 6537773
    Abstract: The present invention provides the nucleotide sequence of the entire genome of Mycoplasma genitalium, SEQ ID NO:1. The present invention further provides the sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use. In addition to the entire genomic sequence, the present invention identifies protein encoding fragments of the genome, and identifies, by position relative to two (2) genes known to flank the origin of replication, any regulatory elements which modulate the expression of the protein encoding fragments of the Mycoplasma genitalium genome.
    Type: Grant
    Filed: October 19, 1995
    Date of Patent: March 25, 2003
    Assignees: The Institute for Genomic Research, Johns Hopkins University, The University of North Carolina at Chapel Hill
    Inventors: Claire M. Fraser, Mark D. Adams, Jeannine D. Gocayne, Clyde A. Hutchison, III, Hamilton O. Smith, J. Craig Venter, Owen White
  • Patent number: 6534630
    Abstract: The present invention relates to a human CTGF-2 polypeptide and DNA (RNA) encoding such polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonist/inhibitors against such polypeptide. Also provided are methods of using the polypeptide therapeutically for enhancing the repair of connective and support tissue, promoting the attachment, fixation and stabilization of tissue implants and enhancing wound healing. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention are also disclosed.
    Type: Grant
    Filed: July 8, 1999
    Date of Patent: March 18, 2003
    Assignee: Human Genome Sciences, Inc.
    Inventors: Haodong Li, Mark D. Adams
  • Patent number: 6528289
    Abstract: The present invention provides the sequencing of the entire genome of Haemophilus influenzae Rd, SEQ ID NO:1. The present invention further provides the sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use. In addition to the entire genomic sequence, the present invention identifies over 1700 protein encoding fragments of the genome and identifies, by position relative to a unique Not I restriction endonuclease site, any regulatory elements which modulate the expression of the protein encoding fragments of the Haemophilus genome.
    Type: Grant
    Filed: August 23, 2000
    Date of Patent: March 4, 2003
    Assignees: Human Genome Sciences, Inc., Johns Hopkins University
    Inventors: Robert D. Fleischmann, Mark D. Adams, Owen White, Hamilton O. Smith, J. Craig Venter
  • Patent number: 6518046
    Abstract: The present invention relates to Human Ck&bgr;-9 polypeptides and DNA (RNA) encoding such chemolcine polypeptides. Moreover, a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such Ck&bgr;-9 polypeptides for the treatment of leukemia, tumors, chronic infections, autoimmune diseases, fibrotic disorders, wound healing and psoriasis. Antagonists against such polypeptides and their use as a therapeutic agent to treat rheumatoid arthritis, autoimmune and chronic inflammatory and infective disease, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed. Diagnostic assays are also disclosed which detect the presence of mutations in the Ck&bgr;-9 coding sequence and over-expression of the Ck&bgr;-9 protein.
    Type: Grant
    Filed: May 19, 1997
    Date of Patent: February 11, 2003
    Assignee: Human Genome Sciences, Inc.
    Inventors: Haodong Li, Mark D. Adams
  • Publication number: 20030027177
    Abstract: The present invention discloses three human DNA repair proteins and DNA (RNA) encoding such proteins and a prodeudre for producing such proteins by recombinant techniques. One of the human DNA repair proteins, hMLH1, has been mapped to chromosome 3 while hMLH2 has been mapped to chromosome 2 and hMLH3 has been mapped to chromosome 7. The polynucleotide sequences of the DNA repair proteins may be used for therapeutic and diagnostic treatments of a hereditary susceptibility to cancer.
    Type: Application
    Filed: February 22, 2002
    Publication date: February 6, 2003
    Applicant: Human Genome Sciences, Inc.
    Inventors: William A. Haseltine, Steven M. Ruben, Ying-Fei Wei, Mark D. Adams, Robert D. Fleischmann, Claire M. Fraser, Rebecca A. Fuldner, Ewen F. Kirkness, Craig A. Rosen
  • Publication number: 20030022314
    Abstract: Human chemokine Beta-10 polypeptides and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemokine polypeptides for the treatment of leukemia, tumors, chronic infections, autoimmune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemokine polypeptides and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed.
    Type: Application
    Filed: April 19, 2002
    Publication date: January 30, 2003
    Applicant: Human Genome Sciences, Inc.
    Inventors: Henrik S. Olsen, Haodong Li, Mark D. Adams, Solange H. L. Gentz, Ralph Alderson, Yuling Li, David Parmelee, John R. White, Edward R. Appelbaum
  • Patent number: 6506581
    Abstract: The present invention provides the sequencing of the entire genome of Haemophilus influenzae Rd, SEQ ID NO:1. The present invention further provides the sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use. In addition to the entire genomic sequence, the present invention identifies over 1700 protein encoding fragments of the genome and identifies, by position relative to a unique Not I restriction endonuclease site, any regulatory elements which modulate the expression of the protein encoding fragments of the Haemophilus genome.
    Type: Grant
    Filed: April 25, 2000
    Date of Patent: January 14, 2003
    Assignees: Human Genome Science, Inc., Johns Hopkins University
    Inventors: Robert D. Fleischmann, Mark D. Adams, Owen White, Hamilton O. Smith, J. Craig Venter
  • Publication number: 20020188110
    Abstract: The present invention discloses transforming growth factor alpha HI polypeptides and polynucleotides encoding such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques and therapeutic uses of the polypeptides which include stimulating wound healing, treating neurological disorders, treating ocular disorders, treating kidney and liver disorders and stimulating embryogenesis and angiogenesis. Also disclosed are antagonists against such polypeptide and their use as a therapeutic to treat neoplasia. Also disclosed are diagnostic assays for detecting altered levels of the polypeptide of the present invention and mutations in the nucleic acid sequences which encode the polypeptides of the present invention.
    Type: Application
    Filed: July 25, 2002
    Publication date: December 12, 2002
    Applicant: Human Genome Sciences, Inc.
    Inventors: Paul S. Meissner, Rebecca A. Fuldner, Ying Fei-Wei, Mark D. Adams
  • Publication number: 20020173007
    Abstract: Human chemokine polypeptides and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemokine polypeptides for the treatment of leukemia, tumors, chronic infections, autoimmune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemokine polypeptides and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention are also disclosed.
    Type: Application
    Filed: June 10, 2002
    Publication date: November 21, 2002
    Applicant: Human Genome Sciences, Inc.
    Inventors: Haodong Li, Mark D. Adams
  • Patent number: 6482606
    Abstract: The present invention discloses three human DNA repair proteins and DNA (RNA) encoding such proteins. The DNA repair proteins may be produced by recombinant DNA techniques. One of the human DNA repair proteins, hmlh1, has been mapped on chromosome 3. The polynucleotide sequences of DNA repair proteins may be used for diagnosis of a hereditary susceptibility to cancer.
    Type: Grant
    Filed: January 27, 1994
    Date of Patent: November 19, 2002
    Assignee: Human Genome Sciences, Inc.
    Inventors: Mark D. Adams, Robert D. Fleischmann, Claire M. Fraser, Rebecca A. Fuldner, Ewen F. Kirkness, William A. Haseltine, Craig A. Rosen, Steve Ruben, Ying-Fei Wei
  • Patent number: 6475487
    Abstract: Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases. A patient is treated by administering an antibody produced against a polypeptide consisting of SEQ ID NO: 2.
    Type: Grant
    Filed: September 18, 2001
    Date of Patent: November 5, 2002
    Assignees: Human Genome Sciences, Inc., SmithKline Beecham Corporation
    Inventors: Gregg A. Hastings, Mark D. Adams, Claire M. Fraser, Norman H. Lee, Ewen F. Kirkness, Judith A. Blake, Lisa M. Fitzgerald, Fred H Drake, Maxine Gowan
  • Patent number: 6475766
    Abstract: Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.
    Type: Grant
    Filed: November 7, 1995
    Date of Patent: November 5, 2002
    Assignees: Human Genome Sciences, Inc., SmithKline Beecham Corporation
    Inventors: Gregg A. Hastings, Mark D. Adams, Claire M. Fraser, Norman H. Lee, Ewen F. Kirkness, Judith A. Blake, Lisa M. Fitzgerald, Fred H. Drake, Maxine Gowan
  • Patent number: 6468765
    Abstract: The present invention provides the sequencing of the entire genome of Haemophilus influenzae Rd, SEQ ID NO:1. The present invention further provides the sequence information stored on computer readable media, and computer-based systems and methods which facilitate its use. In addition to the entire genomic sequence, the present invention identifies over 1700 protein encoding fragments of the genome and identifies, by position relative to a unique Not I restriction endonuclease site, any regulatory elements which modulate the expression of the protein encoding fragments of the Haemophilus genome.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 22, 2002
    Assignees: Human Genome Sciences, Inc., Johns Hopkins University
    Inventors: Robert D. Fleischmann, Mark D. Adams, Owen White, Hamilton O. Smith, J. Craig Venter
  • Publication number: 20020146408
    Abstract: Disclosed are human haemopoietic maturation factor polypeptides and DNA (RNA) encoding such haemopoietic maturation factor polypeptides. Also provided are procedures for producing such polypeptides by recombinant techniques and for using such polypeptides for treating leukemia, auto-immune diseases and blood related disorders. Antagonists against such polypeptides and their use as a therapeutic to prevent expansion of T-cell populations are also disclosed. Diagnostic assays are also disclosed to detect both the presence of mutations in the haemopoietic maturation factor nucleic acid sequences and altered levels of the protein.
    Type: Application
    Filed: December 7, 2001
    Publication date: October 10, 2002
    Applicant: Human Genome Sciences, Inc.
    Inventors: Ewen F. Kirkness, Mark D. Adams, Henrik S. Olsen, Craig A. Rosen
  • Publication number: 20020146791
    Abstract: The present invention relates to human Corpuscles of Stannius polypeptides and DNA (RNA) encoding such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques and antagonists against such polypeptides. Human Corpuscles of Stannius protein inhibits calcium uptake and reduces renal excretion of phosphate. Also provided is a diagnostic assay to detect mutations in the nucleic acid sequence encoding the polypeptide and for altered concentrations of the polypeptide in a sample derived from a host.
    Type: Application
    Filed: April 5, 2002
    Publication date: October 10, 2002
    Applicant: Human Genome Sciences, Inc.
    Inventors: Henrik S. Olsen, Mark D. Adams
  • Publication number: 20020142448
    Abstract: Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.
    Type: Application
    Filed: April 3, 2002
    Publication date: October 3, 2002
    Applicant: Human Genome Sciences, Inc.
    Inventors: Gregg A. Hastings, Mark D. Adams, Claire M. Fraser, Norman H. Lee, Ewen F. Kirkness, Judith A. Blake, Lisa M. Fitzgerald, Fred H. Drake, Maxine Gowan
  • Patent number: 6458349
    Abstract: Human chemokine polypeptides and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemokine polypeptides for the treatment of leukemia, tumors, chronic infections, autoimmune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemokine polypeptides and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention are also disclosed.
    Type: Grant
    Filed: March 3, 1999
    Date of Patent: October 1, 2002
    Assignee: Human Genome Sciences, Inc.
    Inventors: Haodong Li, Mark D. Adams
  • Publication number: 20020132775
    Abstract: Disclosed are human K+ channel polypeptides and DNA (RNA) encoding such K+ channel polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques. Agonists for such K+ channel polypeptides are also disclosed. Such agonists may be used to treat epilepsy, stroke, hypertension, asthma, Parkinson's disease, schizophrenia, anxiety, depression and neurodegeneration. Also disclosed are antagonists against such polypeptides which may be used to treat AIDS, SLE, diabetes, multiple sclerosis and cancer. Also disclosed are diagnostic assays for detecting mutations in the polynucleotide sequences of the present invention.
    Type: Application
    Filed: May 13, 2002
    Publication date: September 19, 2002
    Applicant: Human Genome Sciences, Inc.
    Inventors: Yi Li, Mark D. Adams, Owen R. White
  • Publication number: 20020106734
    Abstract: A human adrenergic receptor polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are agonists for the adrenergic receptor polypeptide which may be used therapeutically to stimulate the adrenergic receptor and antagonist inhibitors against such adrenergic receptor polypeptides and their use therapeutically to antagonize the adrenergic receptor.
    Type: Application
    Filed: September 14, 2001
    Publication date: August 8, 2002
    Applicant: Human Genome Sciences, Inc.
    Inventors: Daniel R. Soppet, Yi Li, Mark D. Adams